At close: December 13 at 4:00:01 PM EST
After hours: December 13 at 4:01:41 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Samuel S. Kintz M.B.A. | Co-Founder, CEO, Secretary & Director | 866.41k | -- | 1986 |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer | 632.67k | -- | 1965 |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer | 686.19k | -- | 1963 |
| Mr. Anish Patel Pharm.D. | Co-Founder & COO | -- | -- | 1981 |
| Mr. Benjamin Hohl | CFO & Head of Corporate Development | 488.5k | -- | 1990 |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | -- | -- | 1977 |
Enliven Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 46
Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Corporate Governance
Enliven Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 12, 2025 at 10:59 AM UTC - March 17, 2025 at 12:00 PM UTC
Enliven Therapeutics, Inc. Earnings Date
Recent Events
April 18, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
IRON Disc Medicine, Inc.
64.89
+0.96%
SYRE Spyre Therapeutics, Inc.
24.12
+0.84%
MLTX MoonLake Immunotherapeutics
51.34
-4.52%
ERAS Erasca, Inc.
2.5600
-2.66%
APGE Apogee Therapeutics, Inc.
44.50
+0.41%
VRDN Viridian Therapeutics, Inc.
17.85
-0.78%
PTGX Protagonist Therapeutics, Inc.
41.08
+1.73%
RARE Ultragenyx Pharmaceutical Inc.
45.78
-2.37%
MLYS Mineralys Therapeutics, Inc.
11.90
-2.22%
ORKA Oruka Therapeutics, Inc.
21.94
+2.91%